Compare Abeona Therapeutics Inc (ABEO) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Realty Income Corp — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while Realty Income Corp trades at $62.02 (market cap $58.56B). The key difference: Realty Income Corp is far larger — about 138× Abeona Therapeutics Inc's market cap, and Realty Income Corp pays a 5.25% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | O | |
|---|---|---|
Market Cap | $424.33M | $58.56B |
Sector | Health | Real Estate |
52-Week High | $7.45 | $67.56 |
52-Week Low | $4.17 | $55.93 |
Enterprise Value | $279.23M | $89.19B |
Dividend Yield | — | 5.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
Realty Income (O) trades at $62.51, up 0.24% today, with a bearish technical signal from moving averages but bullish oscillators like RSI. The REIT reported Q2 2026 AFFO of $1.09 per share, matching estimates, and raised full-year guidance, supported by a 98.8% occupancy rate. Recent news highlights its high dividend yield and 115th consecutive quarterly increase, alongside a $6 billion data center joint venture announced in August 2026.
Outlook: Strong dividend growth and strategic expansion into data centers offer upside, but high P/E of 45.63 and recent EPS misses pose valuation risks. Analysts target $67.13 consensus, implying modest growth, with debt-to-asset ratio rising to 39.93% in 2025 signaling financial leverage concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
